The heparin market would grow at a CAGR of 4.17% over the predicted time frame. The market is expected to increase in value from US$ 10.53 Bn in 2022 to US$ 14.6 Bn in 2030.
The on heparin
Market, which provides a business strategy, research & development
activities, concise outline of the market valuation, valuable insights
pertaining to market share, size, supply chain analysis, competitive landscape
and regional proliferation of this industry.
Download
Free Sample@ https://www.precedenceresearch.com/sample/1754
Report Scope of the Heparin Market
| Report Coverage | Details |
| Market Size by 2030 | USD 14.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 4.17% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Type, Route of Administration, Packaging, Container, Therapeutics, Treatment, Availability, Application, Source, Ingredients, Strength, End Use, Distribution Channel, Geography |
A recent
report provides crucial insights along with application based and forecast
information in the Global Heparin Market. The report provides a comprehensive
analysis of key factors that are expected to drive the growth of this market.
This study also provides a detailed overview of the opportunities along with
the current trends observed in the Heparin market.
A
quantitative analysis of the industry is compiled for a period of 10 years in
order to assist players to grow in the market. Insights on specific revenue
figures generated are also given in the report, along with projected revenue at
the end of the forecast period.
Companies
and Manufacturers Covered
The study
covers key players operating in the market along with prime schemes and
strategies implemented by each player to hold high positions in the industry.
Such a tough vendor landscape provides a competitive outlook of the industry,
consequently existing as a key insight. These insights were thoroughly analysed
and prime business strategies and products that offer high revenue generation
capacities were identified. Key players of the global Heparin market are
included as given below:
Heparin Market Key Players
- GlaxoSmithKline plc
- Pfizer, Inc.
- Baxter
- Leo Pharma A/S
- Sanofi
- Dr. Reddy’s Laboratories Ltd.
- Aspen Holdings
- B. Braun Medical Inc.
- Fresenius SE & Co. KGaA
- Teva Pharmaceutical Industries Ltd.
Market Segments
- Low Molecular Weight Heparin
- Ultra-low Molecular Weight Heparin
- Unfractionated Heparin
By Route of Administration
- Intravenous
- Subcutaneous
By Packaging
- Glass
- Plastic
By Container
- Bottles
- Bags
- Vials
- Others
By Therapeutics
- Cardiovascular
- Respiratory
- Oncology
- Nephrology
- CNS
- Others
By Treatment
- Deep Vein Thrombosis
- Pulmonary Embolism
- Arterial Thromboembolism
- Others
By Availability
- Raw
- Processed
By Application
- Venous Thromboembolism
- Atrial Fibrillation
- Renal Impairment
- Coronary Artery Disease
- Others
By Source
- Bovine
- Porcine
By Ingredients
- Sodium
- Calcium
- Others
By Strength
- 10 Unit
- 100 Unit
- 1000 Unit
- 5000 Unit
- 10000 Unit
- 25000 Unit
- Others
By End Use
- Hospitals
- Clinics
- Homecare
- Ambulatory Surgical Centres
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy and Drug Store
- Online Pharmacy
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global heparin
market based on product, and region
- To provide detailed information regarding the major
factors influencing the growth of the market (drivers, opportunities, and
industry-specific challenges)
- To strategically analyze micromarkets1 with respect to
individual growth trends, future prospects, and contributions to the total
market
- To analyze opportunities in the market for stakeholders
and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to
four main regions—North America,
Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively
analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as
acquisitions, expansions, new product launches, and partnerships in the heparin
market
Table of Content
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Heparin Market, By Type
7.1. Heparin Market, by Type, 2022-2030
7.1.1. Low Molecular Weight Heparin
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Ultra-low Molecular Weight Heparin
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Unfractionated Heparin
7.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Heparin Market, By Route of Administration
8.1. Heparin Market, by Route of Administration, 2022-2030
8.1.1. Intravenous
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Subcutaneous
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Heparin Market, By Packaging
9.1. Heparin Market, by Packaging, 2022-2030
9.1.1. Glass
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Plastic
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Heparin Market, By Container
10.1. Heparin Market, by Container, 2022-2030
10.1.1. Bottles
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Bags
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Vials
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Heparin Market, By Therapeutics
11.1. Heparin Market, by Therapeutics, 2022-2030
11.1.1. Cardiovascular
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Respiratory
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Oncology
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Nephrology
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. CNS
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Heparin Market, By Treatment
12.1. Heparin Market, by Treatment, 2022-2030
12.1.1. Deep Vein Thrombosis
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Pulmonary Embolism
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Arterial Thromboembolism
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. Others
12.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Heparin Market, By Availability
13.1. Heparin Market, by Availability, 2022-2030
13.1.1. Raw
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Processed
13.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Heparin Market, By Application
14.1. Heparin Market, by Application, 2022-2030
14.1.1. Venous Thromboembolism
14.1.1.1. Market Revenue and Forecast (2017-2030)
14.1.2. Atrial Fibrillation
14.1.2.1. Market Revenue and Forecast (2017-2030)
14.1.3. Renal Impairment
14.1.3.1. Market Revenue and Forecast (2017-2030)
14.1.4. Coronary Artery Disease
14.1.4.1. Market Revenue and Forecast (2017-2030)
14.1.5. Others
14.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 15. Global Heparin Market, By Source
15.1. Heparin Market, by Source, 2022-2030
15.1.1. Bovine
15.1.1.1. Market Revenue and Forecast (2017-2030)
15.1.2. Porcine
15.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 16. Global Heparin Market, By Ingredients
16.1. Heparin Market, by Ingredients, 2022-2030
16.1.1. Sodium
16.1.1.1. Market Revenue and Forecast (2017-2030)
16.1.2. Calcium
16.1.2.1. Market Revenue and Forecast (2017-2030)
16.1.3. Others
16.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 17. Global Heparin Market, By Strength
17.1. Heparin Market, by Strength, 2022-2030
17.1.1. 10 Unit
17.1.1.1. Market Revenue and Forecast (2017-2030)
17.1.2. 100 Unit
17.1.2.1. Market Revenue and Forecast (2017-2030)
17.1.3. 1000 Unit
17.1.3.1. Market Revenue and Forecast (2017-2030)
17.1.4. 5000 Unit
17.1.4.1. Market Revenue and Forecast (2017-2030)
17.1.5. 10000 Unit
17.1.5.1. Market Revenue and Forecast (2017-2030)
17.1.6. 25000 Unit
17.1.6.1. Market Revenue and Forecast (2017-2030)
17.1.7. Others
17.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 18. Global Heparin Market, By End Use
18.1. Heparin Market, by End Use, 2022-2030
18.1.1. Hospitals
18.1.1.1. Market Revenue and Forecast (2017-2030)
18.1.2. Clinics
18.1.2.1. Market Revenue and Forecast (2017-2030)
18.1.3. Homecare
18.1.3.1. Market Revenue and Forecast (2017-2030)
18.1.4. Ambulatory Surgical Centres
18.1.4.1. Market Revenue and Forecast (2017-2030)
18.1.5. Others
18.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 19. Global Heparin Market, By Distribution Channel
19.1. Heparin Market, by Distribution Channel, 2022-2030
19.1.1. Hospital Pharmacy
19.1.1.1. Market Revenue and Forecast (2017-2030)
19.1.2. Retail Pharmacy and Drug Store
19.1.2.1. Market Revenue and Forecast (2017-2030)
19.1.3. Online Pharmacy
19.1.3.1. Market Revenue and Forecast (2017-2030)
19.1.4. Others
19.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 20. Global Heparin Market, Regional Estimates and Trend Forecast
20.1. North America
20.1.1. Market Revenue and Forecast, by Type (2017-2030)
20.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.1.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.1.4. Market Revenue and Forecast, by Container (2017-2030)
20.1.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.1.6. Market Revenue and Forecast, by Availability (2017-2030)
20.1.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.1.8. Market Revenue and Forecast, by Application (2017-2030)
20.1.9. Market Revenue and Forecast, by Source (2017-2030)
20.1.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.1.11. Market Revenue and Forecast, by Strength (2017-2030)
20.1.12. Market Revenue and Forecast, by End Use (2017-2030)
20.1.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.1.12. U.S.
20.1.12.1. Market Revenue and Forecast, by Type (2017-2030)
20.1.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.1.12.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.1.12.4. Market Revenue and Forecast, by Container (2017-2030)
20.1.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.1.12.6. Market Revenue and Forecast, by Availability (2017-2030)
20.1.12.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.1.12.8. Market Revenue and Forecast, by Application (2017-2030)
20.1.12.9. Market Revenue and Forecast, by Source (2017-2030)
20.1.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.1.12.11. Market Revenue and Forecast, by Strength (2017-2030)
20.1.12.12. Market Revenue and Forecast, by End Use (2017-2030)
20.1.12.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.1.13. Rest of North America
20.1.13.1. Market Revenue and Forecast, by Type (2017-2030)
20.1.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.1.13.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.1.13.4. Market Revenue and Forecast, by Container (2017-2030)
20.1.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.1.13.6. Market Revenue and Forecast, by Availability (2017-2030)
20.1.13.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.1.13.8. Market Revenue and Forecast, by Application (2017-2030)
20.1.13.9. Market Revenue and Forecast, by Source (2017-2030)
20.1.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.1.13.11. Market Revenue and Forecast, by Strength (2017-2030)
20.1.12.12. Market Revenue and Forecast, by End Use (2017-2030)
20.1.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.2. Europe
20.2.1. Market Revenue and Forecast, by Type (2017-2030)
20.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.2.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.2.4. Market Revenue and Forecast, by Container (2017-2030)
20.2.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.2.6. Market Revenue and Forecast, by Availability (2017-2030)
20.2.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.2.8. Market Revenue and Forecast, by Application (2017-2030)
20.2.9. Market Revenue and Forecast, by Source (2017-2030)
20.2.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.2.11. Market Revenue and Forecast, by Strength (2017-2030)
20.2.12. Market Revenue and Forecast, by End Use (2017-2030)
20.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.2.12. UK
20.2.12.1. Market Revenue and Forecast, by Type (2017-2030)
20.2.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.2.12.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.2.12.4. Market Revenue and Forecast, by Container (2017-2030)
20.2.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.2.12.6. Market Revenue and Forecast, by Availability (2017-2030)
20.2.12.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.2.12.8. Market Revenue and Forecast, by Application (2017-2030)
20.2.12.9. Market Revenue and Forecast, by Source (2017-2030)
20.2.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.2.12.11. Market Revenue and Forecast, by Strength (2017-2030)
20.2.12.12. Market Revenue and Forecast, by End Use (2017-2030)
20.2.12.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.2.13. Germany
20.2.13.1. Market Revenue and Forecast, by Type (2017-2030)
20.2.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.2.13.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.2.13.4. Market Revenue and Forecast, by Container (2017-2030)
20.2.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.2.13.6. Market Revenue and Forecast, by Availability (2017-2030)
20.2.13.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.2.13.8. Market Revenue and Forecast, by Application (2017-2030)
20.2.13.9. Market Revenue and Forecast, by Source (2017-2030)
20.2.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.2.13.11. Market Revenue and Forecast, by Strength (2017-2030)
20.2.13.12. Market Revenue and Forecast, by End Use (2017-2030)
20.2.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.2.14. France
20.2.14.1. Market Revenue and Forecast, by Type (2017-2030)
20.2.14.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.2.14.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.2.14.4. Market Revenue and Forecast, by Container (2017-2030)
20.2.14.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.2.14.6. Market Revenue and Forecast, by Availability (2017-2030)
20.2.14.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.2.14.8. Market Revenue and Forecast, by Application (2017-2030)
20.2.14.9. Market Revenue and Forecast, by Source (2017-2030)
20.2.14.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.2.14.11. Market Revenue and Forecast, by Strength (2017-2030)
20.2.14.12. Market Revenue and Forecast, by End Use (2017-2030)
20.2.14.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.2.15. Rest of Europe
20.2.15.1. Market Revenue and Forecast, by Type (2017-2030)
20.2.15.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.2.15.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.2.15.4. Market Revenue and Forecast, by Container (2017-2030)
20.2.15.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.2.15.6. Market Revenue and Forecast, by Availability (2017-2030)
20.2.15.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.2.15.8. Market Revenue and Forecast, by Application (2017-2030)
20.2.15.9. Market Revenue and Forecast, by Source (2017-2030)
20.2.15.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.2.15.11. Market Revenue and Forecast, by Strength (2017-2030)
20.2.15.12. Market Revenue and Forecast, by End Use (2017-2030)
20.2.15.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.3. APAC
20.3.1. Market Revenue and Forecast, by Type (2017-2030)
20.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.3.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.3.4. Market Revenue and Forecast, by Container (2017-2030)
20.3.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.3.6. Market Revenue and Forecast, by Availability (2017-2030)
20.3.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.3.8. Market Revenue and Forecast, by Application (2017-2030)
20.3.9. Market Revenue and Forecast, by Source (2017-2030)
20.3.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.3.11. Market Revenue and Forecast, by Strength (2017-2030)
20.3.12. Market Revenue and Forecast, by End Use (2017-2030)
20.3.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.3.12. India
20.3.12.1. Market Revenue and Forecast, by Type (2017-2030)
20.3.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.3.12.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.3.12.4. Market Revenue and Forecast, by Container (2017-2030)
20.3.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.3.12.6. Market Revenue and Forecast, by Availability (2017-2030)
20.3.12.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.3.12.8. Market Revenue and Forecast, by Application (2017-2030)
20.3.12.9. Market Revenue and Forecast, by Source (2017-2030)
20.3.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.3.12.11. Market Revenue and Forecast, by Strength (2017-2030)
20.3.12.12. Market Revenue and Forecast, by End Use (2017-2030)
20.3.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.3.13. China
20.3.13.1. Market Revenue and Forecast, by Type (2017-2030)
20.3.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.3.13.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.3.13.4. Market Revenue and Forecast, by Container (2017-2030)
20.3.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.3.13.6. Market Revenue and Forecast, by Availability (2017-2030)
20.3.13.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.3.13.8. Market Revenue and Forecast, by Application (2017-2030)
20.3.13.9. Market Revenue and Forecast, by Source (2017-2030)
20.3.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.3.13.11. Market Revenue and Forecast, by Strength (2017-2030)
20.3.13.12. Market Revenue and Forecast, by End Use (2017-2030)
20.3.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.3.14. Japan
20.3.14.1. Market Revenue and Forecast, by Type (2017-2030)
20.3.14.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.3.14.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.3.14.4. Market Revenue and Forecast, by Container (2017-2030)
20.3.14.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.3.14.6. Market Revenue and Forecast, by Availability (2017-2030)
20.3.14.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.3.14.8. Market Revenue and Forecast, by Application (2017-2030)
20.3.14.9. Market Revenue and Forecast, by Source (2017-2030)
20.3.14.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.3.14.11. Market Revenue and Forecast, by Strength (2017-2030)
20.3.14.12. Market Revenue and Forecast, by End Use (2017-2030)
20.3.14.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.3.15. Rest of APAC
20.3.15.1. Market Revenue and Forecast, by Type (2017-2030)
20.3.15.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.3.15.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.3.15.4. Market Revenue and Forecast, by Container (2017-2030)
20.3.15.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.3.15.6. Market Revenue and Forecast, by Availability (2017-2030)
20.3.15.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.3.15.8. Market Revenue and Forecast, by Application (2017-2030)
20.3.15.9. Market Revenue and Forecast, by Source (2017-2030)
20.3.15.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.3.15.11. Market Revenue and Forecast, by Strength (2017-2030)
20.3.15.12. Market Revenue and Forecast, by End Use (2017-2030)
20.3.15.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.4. MEA
20.4.1. Market Revenue and Forecast, by Type (2017-2030)
20.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.4.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.4.4. Market Revenue and Forecast, by Container (2017-2030)
20.4.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.4.6. Market Revenue and Forecast, by Availability (2017-2030)
20.4.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.4.8. Market Revenue and Forecast, by Application (2017-2030)
20.4.9. Market Revenue and Forecast, by Source (2017-2030)
20.4.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.4.11. Market Revenue and Forecast, by Strength (2017-2030)
20.4.12. Market Revenue and Forecast, by End Use (2017-2030)
20.4.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.4.12. GCC
20.4.12.1. Market Revenue and Forecast, by Type (2017-2030)
20.4.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.4.12.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.4.12.4. Market Revenue and Forecast, by Container (2017-2030)
20.4.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.4.12.6. Market Revenue and Forecast, by Availability (2017-2030)
20.4.12.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.4.12.8. Market Revenue and Forecast, by Application (2017-2030)
20.4.12.9. Market Revenue and Forecast, by Source (2017-2030)
20.4.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.4.12.11. Market Revenue and Forecast, by Strength (2017-2030)
20.4.12.12. Market Revenue and Forecast, by End Use (2017-2030)
20.4.12.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.4.13. North Africa
20.4.13.1. Market Revenue and Forecast, by Type (2017-2030)
20.4.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.4.13.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.4.13.4. Market Revenue and Forecast, by Container (2017-2030)
20.4.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.4.13.6. Market Revenue and Forecast, by Availability (2017-2030)
20.4.13.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.4.13.8. Market Revenue and Forecast, by Application (2017-2030)
20.4.13.9. Market Revenue and Forecast, by Source (2017-2030)
20.4.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.4.13.11. Market Revenue and Forecast, by Strength (2017-2030)
20.4.13.12. Market Revenue and Forecast, by End Use (2017-2030)
20.4.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.4.14. South Africa
20.4.14.1. Market Revenue and Forecast, by Type (2017-2030)
20.4.14.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.4.14.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.4.14.4. Market Revenue and Forecast, by Container (2017-2030)
20.4.14.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.4.14.6. Market Revenue and Forecast, by Availability (2017-2030)
20.4.14.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.4.14.8. Market Revenue and Forecast, by Application (2017-2030)
20.4.14.9. Market Revenue and Forecast, by Source (2017-2030)
20.4.14.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.4.14.11. Market Revenue and Forecast, by Strength (2017-2030)
20.4.14.12. Market Revenue and Forecast, by End Use (2017-2030)
20.4.14.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.4.15. Rest of MEA
20.4.15.1. Market Revenue and Forecast, by Type (2017-2030)
20.4.15.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.4.15.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.4.15.4. Market Revenue and Forecast, by Container (2017-2030)
20.4.15.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.4.15.6. Market Revenue and Forecast, by Availability (2017-2030)
20.4.15.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.4.15.8. Market Revenue and Forecast, by Application (2017-2030)
20.4.15.9. Market Revenue and Forecast, by Source (2017-2030)
20.4.15.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.4.15.11. Market Revenue and Forecast, by Strength (2017-2030)
20.4.15.12. Market Revenue and Forecast, by End Use (2017-2030)
20.4.15.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.5. Latin America
20.5.1. Market Revenue and Forecast, by Type (2017-2030)
20.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.5.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.5.4. Market Revenue and Forecast, by Container (2017-2030)
20.5.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.5.6. Market Revenue and Forecast, by Availability (2017-2030)
20.5.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.5.8. Market Revenue and Forecast, by Application (2017-2030)
20.5.9. Market Revenue and Forecast, by Source (2017-2030)
20.5.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.5.11. Market Revenue and Forecast, by Strength (2017-2030)
20.5.12. Market Revenue and Forecast, by End Use (2017-2030)
20.5.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.5.12. Brazil
20.5.12.1. Market Revenue and Forecast, by Type (2017-2030)
20.5.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.5.12.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.5.12.4. Market Revenue and Forecast, by Container (2017-2030)
20.5.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.5.12.6. Market Revenue and Forecast, by Availability (2017-2030)
20.5.12.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.5.12.8. Market Revenue and Forecast, by Application (2017-2030)
20.5.12.9. Market Revenue and Forecast, by Source (2017-2030)
20.5.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.5.12.11. Market Revenue and Forecast, by Strength (2017-2030)
20.5.12.12. Market Revenue and Forecast, by End Use (2017-2030)
20.5.12.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
20.5.13. Rest of LATAM
20.5.13.1. Market Revenue and Forecast, by Type (2017-2030)
20.5.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
20.5.13.3. Market Revenue and Forecast, by Packaging (2017-2030)
20.5.13.4. Market Revenue and Forecast, by Container (2017-2030)
20.5.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)
20.5.13.6. Market Revenue and Forecast, by Availability (2017-2030)
20.5.13.7. Market Revenue and Forecast, by Treatment (2017-2030)
20.5.13.8. Market Revenue and Forecast, by Application (2017-2030)
20.5.13.9. Market Revenue and Forecast, by Source (2017-2030)
20.5.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)
20.5.13.11. Market Revenue and Forecast, by Strength (2017-2030)
20.5.13.12. Market Revenue and Forecast, by End Use (2017-2030)
20.5.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 21. Company Profiles
21.1. GlaxoSmithKline plc
21.1.1. Company Overview
21.1.2. Product Offerings
21.1.3. Financial Performance
21.1.4. Recent Initiatives
21.2. Pfizer, Inc.
21.2.1. Company Overview
21.2.2. Product Offerings
21.2.3. Financial Performance
21.2.4. Recent Initiatives
21.3. Baxter
21.3.1. Company Overview
21.3.2. Product Offerings
21.3.3. Financial Performance
21.3.4. Recent Initiatives
21.4. Leo Pharma A/S
21.4.1. Company Overview
21.4.2. Product Offerings
21.4.3. Financial Performance
21.4.4. Recent Initiatives
21.5. Sanofi
21.5.1. Company Overview
21.5.2. Product Offerings
21.5.3. Financial Performance
21.5.4. Recent Initiatives
21.6. Dr. Reddy’s Laboratories Ltd.
21.6.1. Company Overview
21.6.2. Product Offerings
21.6.3. Financial Performance
21.6.4. Recent Initiatives
21.7. Aspen Holdings
21.7.1. Company Overview
21.7.2. Product Offerings
21.7.3. Financial Performance
21.7.4. Recent Initiatives
21.8. B. Braun Medical Inc.
21.8.1. Company Overview
21.8.2. Product Offerings
21.8.3. Financial Performance
21.8.4. Recent Initiatives
21.9. Fresenius SE & Co. KGaA
21.9.1. Company Overview
21.9.2. Product Offerings
21.9.3. Financial Performance
21.9.4. Recent Initiatives
21.10. Teva Pharmaceutical Industries Ltd.
21.10.1. Company Overview
21.10.2. Product Offerings
21.10.3. Financial Performance
21.10.4. Recent Initiatives
Chapter 22. Research Methodology
22.1. Primary Research
22.2. Secondary Research
22.3. Assumptions
Chapter 23. Appendix
23.1. About Us
23.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments